Jointown has nominated Li Zhongchao as a candidate for non-independent director of the sixth board of directors, and appointed Liu Qingxin as chief compliance officer. Li Zhongchao's director term will run from the date of approval by the shareholders' meeting until the expiry of the board's term, while Liu Qingxin will take full charge of compliance management for the same term. In addition, Wu Xuesong resigned as director on 26 July 2026 due to work adjustments, and the company stated that this will not affect the normal operation of the board. In the first quarter of 2026, Jointown achieved revenue of 44.783 billion yuan and net profit attributable to the parent company of 733 million yuan.
Jointown Pharmaceutical Group Co LtdBoard and compliance officer changes are routine governance moves; no clear positive or negative impact on operations or financials.